<DOC>
	<DOCNO>NCT01952444</DOCNO>
	<brief_summary>Evaluate safety tolerability intravenous ( IV ) ETI-204 alone presence IV oral ciprofloxacin</brief_summary>
	<brief_title>Open-Label , Randomized , Parallel Group Study Assess Safety , Tolerability PK ETI-204 Alone Presence Ciprofloxacin Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Anthrax</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>1 . Females males 18 60 year age 2 . All female , regardless childbearing potential , must negative serum beta human chorionic gonadotropin ( βhCG ) pregnancy test Screening Day 1 3 . Females childbearing potential ( i.e. , postmenopausal surgically sterile ) must agree practice abstinence use medically accept method contraception time Screening 30 day final study visit . Acceptable method contraception include diaphragm spermicide ; sponge spermicide ; condom spermicide ; intrauterine device condom spermicide . The following contraceptive method acceptable used condom spermicide : birth control pill , birth control patch , vaginal ring , hormone skin , hormone injection 4 . Postmenopausal female , define female amenorrhea least 12 month either naturally follow cessation exogenous hormonal treatment , folliclestimulating hormone ( FSH ) level &gt; 40 mIU/mL Screening 5 . Females undergone surgical sterilization , include hysterectomy , bilateral oophorectomy , bilateral salpingectomy , tubal ligation , tubal essure ≥ 3 month prior Screening . Tubal essure require radiological confirmation occlusion fallopian tube . Subjects provide documentation may participate agree follow method contraception specify Inclusion Criterion # 3 6 . Males must agree practice abstinence use condom spermicide refrain sperm donation study 30 day final study visit . Note apply male undergone vasectomy provide documentation confirmatory sperm count 3 month post procedure . 7 . Provide write informed consent 8 . Willing comply study restriction ( see Section 4.5.3 complete list study restriction ) 1 . Pregnant lactate woman 2 . Clinicallysignificant comorbidity would interfere completion study procedures objective compromise subject 's safety 3 . Supine systolic blood pressure ( BP ) ≥ 150 mmHg ≤ 90 mmHg diastolic BP ≥ 95 mmHg 4 . Use H1 receptor antagonist ( i.e . antihistamine ) within 5 day prior Day 1 5 . Evidence drug alcohol abuse determine Investigator , within 6 month Day 1 6 . Positive test result drug abuse ( exception medically prescribed drug ) Screening Day 1 7 . Positive test alcohol Screening Day 1 8 . Treatment investigational agent within 30 day five halflives investigational agent Day 1 ( whichever longer ) 9 . Congenital acquire immunodeficiency syndrome 10 . Prior solid organ bone marrow transplant 11 . Positive test Hepatitis B ( surface antigen ) , Hepatitis C , human immunodeficiency virus ( HIV ) Screening 12 . History prior treatment anthrax exposure prior anthrax infection 13 . Prior immunization approve investigational anthrax vaccine prior treatment investigational anthrax treatment ( i.e. , ETI204 , raxibacumab , anthrax immune globulin ) 14 . Military personnel deploy 1990 , unless subject provide documentation demonstrate previously receive approved investigational anthrax vaccine 15 . Therapeutic use systemic steroid , immunosuppressive agent , anticoagulant , antiarrhythmic within 1 year prior Day 1 ; single short course ( i.e. , less 14 day ) systemic steroid therapy allow provide conclude 6 month prior Day 1 16 . Donation loss &gt; 500 mL blood within 30 day plasma within 7 day Day 1 17 . Prior stroke , epilepsy , relapse degenerative CNS disease , relapse degenerative ocular disease 18 . Myocardial infarction acute coronary syndrome past 5 year , active angina pectoris , heart failure ( New York Heart Association scale &gt; I ) 19 . History chronic liver disease 20 . Calculated creatinine clearance ( CrCl ) &lt; 30 mL/min use CockcroftGault equation ( see Section 5.1 ) 21 . Any clinically significant abnormality , Investigator 's opinion , electrocardiogram ( ECG ) clinical laboratory test ( hematology , clinical chemistry , urinalysis ) Screening ; range result may repeat confirm 22 . History allergic hypersensitivity reaction therapeutic antibody immunoglobulins 23 . History malignant neoplasm within last 5 year , exception adequately treat localized situ nonmelanoma carcinoma skin ( e.g . basal cell carcinoma ) cervix 24 . Subjects , opinion Investigator , suitable candidate enrollment may comply requirement study Exclusion Criteria Specific Use Ciprofloxacin 1 . Hypersensitivity fluoroquinolone 2 . At increase risk Clostridium . difficile ( C. difficile ) infection ( e.g. , prior systemic antibiotic therapy inhospital stay great 2 night past 6 month , abdominal surgery within 3 month prior Day 1 , chronic inflammatory bowel disease prior C. difficile infection ) 3 . Any medical condition may require repeat course antibiotic , e.g. , recurrent urinary tract respiratory infection . A short course ( i.e.≤ 10 day ) antibiotic within 6 month prior Day 1 exclusionary . 4 . A history tendon rupture 5 . Subjects smoke used tobacco nicotine containing product within 3 month Day 1 . 6 . Use cationcontaining drug food supplement within 2 day prior Day 1 7 . Use protheophylline , theophylline , methylxanthine , tizanidine , drug metabolize via cytochrome P450 1A ( CYP1A ) within 30 day prior Day 1 8 . Use glyburide , cyclosporine , didanosine , methotrexate , probenecid medication prolong QT interval within 30 day prior Day 1 within 5 halflives Day 1 , whichever longer 9 . Subjects high risk QT prolongation , include : 1 . Baseline prolongation QTcF ≥ 500 msec 2 . Risk factor Torsade de Pointes , include hypocalcemia , hypokalemia , sudden death unknown cause close family member ( i.e . biological mother , father sibling ) , near drown episode , family history either RomanoWard syndrome Jervell LangeNielson syndrome 3 . The use concomitant medication prolong QT interval within 30 day prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>